Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen. This study has been completed. Sponsor: medac GmbH. Collaborator: PPD. Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen. More evidence-based studies on psoriasis subjects are needed to explore the practical application of subcutaneous methotrexate as a treatment option for severe recalcitrant psoriasis. Bioavailability in patient with psoriasis: Metoject prefilled pen.
Alternative Names: Methotrexate ready-to-use autopen; Metoject prefilled pen; 1 pre-filled pen with 0.15 ml solution contains 7.5 mg methotrexate. Dosage in patients with psoriasis vulgaris and psoriatic arthritis:. Note:If changing the oral application to parenteral administration a reduction of the dose may be required due to the variable bioavailability of methotrexate after oral administration. Metex 50mg/ml – about metoject: How is metoject taken?
Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen. Methods: The study enrolled 403 patients with rheumatoid or psoriatic arthritis. The high-concentration formulation consisted of a prefilled syringe with MTX 50 mg/ml solution and a pre-attached needle.
Methotrexate Subcutaneous Auto-injection
This study is conducted to assess the relative bioavailability of MTX administered subcutaneously via a prefilled pen (50mg/mL) compared with MTX administered via IM injection (25mg/mL). Methotrexate Injection (USP 25 mg/mL Hospira) in Patients With Psoriasis.